Please login to the form below

Not currently logged in
Email:
Password:

Early end for AZ zibotentan study

AstraZeneca has announced an early end to its phase III trial investigating zibotentan in prostate cancer patients due to negative results from an efficacy review

AstraZeneca (AZ) has announced an early end to its phase III trial investigating zibotentan in prostate cancer patients due to negative results from an efficacy review.

The trial, which studied the effectiveness of zibotentan by itself in patients with non-metastatic castrate-resistant prostate cancer (CRPC), was halted after a review from an independent data monitoring committee indicated the drug was unlikely to meet its primary efficacy endpoints concerning progression free survival and overall survival.

A previous trial by AZ investigating zibotentan had already been stopped after negative results were recorded for use of the drug in men with CRPC that had metastasised. Both studies are part of the ENTHUSE programme.

A separate trial in the ENTHUSE programme, investigating the use of zibotentan in combination with chemotherapy in patients for whom the disease has metastasised, is set to continue. Results are expected in the second half of 2011.

The discontinuation of the trial follows the decision by the US Food and Drug Adminstration to deny approval for AZ's potential acute coronary syndrome therapy Brilinta (ticagrelor).

AZ also reported a decrease in profit of two per cent for the fourth quarter of 2010 in recent financial results.

7th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics